Aignostics

Feature differentiation: - Aignostics emphasizes foundation models and a productized TME analytics application; it reports cell-level/high-resolution spatial TME outputs and a large set of quantitative features per slide. - PathAI emphasizes an integrated platform plus a portfolio of AI models and documents clinical/regulatory activities. - Proscia emphasizes an enterprise software platform for managing and operationalizing pathology data. Pricing comparison: - None of the vendors publicly expose full transparent pricing for enterprise buyers. Expect negotiated pricing based on volume, use case (RUO vs clinical), integrations, and validation requirements. Market adoption signals: - PathAI public communications highlight enterprise deployments and clinical/regulatory activity. - Aignostics indicates fundraising activity, partnerships (e.g., Mayo Clinic), and continued product development; these are indicators of vendor activity rather than independent measures of market share. When customers choose competitors instead: - Choose PathAI or Proscia when there is a need for a complete digital pathology operational platform and/or clinical diagnostic workflows. - Choose open or research models when an organization requires full control over models and has internal ML engineering capacity, accepting more engineering and validation effort.